Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05215574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05215574
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 130 participants
Conditions and interventions
Conditions
- Pancreatic Cancer
- Breast Cancer
- Gastric Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Endocervical Cancer
- Squamous Cell Carcinoma of Head and Neck
- Bladder Urothelial Cancer
- Colorectal Carcinoma
- Esophageal Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Prostate Cancer
- Melanoma
- Mesothelioma
- Cholangiocarcinoma
Interventions
- NGM831 Drug
- NGM831 plus pembrolizumab (KEYTRUDA®) Drug
- NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2022 (Actual)
- Primary completion
- Jul 2025 (Estimated)
- Completion
- Mar 2026 (Estimated)
- Last update posted
- Oct 10, 2024
2022 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NGM Clinical Study Site | Gilbert | Arizona | 85234 | — |
| NGM Clinical Study Site | Los Angeles | California | 90025 | — |
| NGM Clinical Study Site | Sarasota | Florida | 34232 | — |
| NGM Clinical Study Site | Tampa | Florida | 33612 | — |
| NGM Clinical Study Site | Grand Rapids | Michigan | 49546 | — |
| NGM Clinical Study Site | New York | New York | 10016 | — |
| NGM Clinical Study Site | Oklahoma City | Oklahoma | 73104 | — |
| NGM Clinical Study Site | Austin | Texas | 78758 | — |
| NGM Clinical Study Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05215574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 10, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05215574 live on ClinicalTrials.gov.